Free Newsletter
Pfizer's Prevnar and Sanofi's ActHIB cleared for Japanese market
After nearly three weeks of suspended vaccinations, Japan has cleared the path for Sanofi-Aventis' ActHIB and Pfizer's Prevnar--marketed as Prevenar--to return to the Japanese market as soon as April 1. The vaccines, ActHIB for hemophilius influenza and meningitis and pneumonia preventative Prevnar, were originally called off the market after five children between the ages of six months and two years died after receiving one or both of the vaccines. Soon after, the Japanese health ministry cleared the vaccines of any connection to the deaths, but the embargo remained in place.
Both companies released statements noting that the Ministry of Health, Labour, and Welfare's Safety Measures Investigation Committee and Post-Vaccination Adverse Event Study panel reaffirmed the vaccines' innocence in the children's deaths.
- see the WSJ piece
- read Bloomberg's coverage
Related Articles:
Japan finds no vaccine link to child deaths
Japan suspends Pfizer, Sanofi shots after deaths
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: